# Remepy

> Remepy develops investigational Hybrid Drugs that pair prescription medicines with personalized therapeutic apps. Its lead program, Hybridopa, combines levodopa with digital interventions for Parkinson’s disease. The company pursues pharmaceutical co-development partnerships, including a collaboration with Merck KGaA, Darmstadt, Germany, and reported $62 million in total financing in August 2026.

- **Founded:** 2022
- **Headquarters:** New York, United States
- **Founders:** Michal Tsur (Co-founder and Co-CEO), Or Shoval (Co-founder and Co-CEO), Amir Amedi (Co-founder and Chief Scientific Officer), Eran Etam (Co-founder and Chief Technology Officer)
- **Products:** Hybridopa, DopApp, Hybrid Drug platform / Digital Molecules
- **Notable:** Peer-reviewed Parkinson’s pilot published in Brain Communications on May 20, 2026., Related brain-connectivity research published in npj Parkinson’s Disease in July 2026., Announced pharmaceutical collaboration with Merck KGaA in April 2026.

## Products & services

- **Hybridopa** — Investigational Parkinson’s program pairing levodopa with a therapeutic digital protocol; Phase IIa results reported in May 2026, with global Phase III planned for Q4 2026. Not FDA approved.
- **DopApp** — Parkinson’s therapeutic app studied alongside stable levodopa therapy, with motor, speech, psychological, spatial-navigation and walking components.
- **Hybrid Drug platform / Digital Molecules** — Personalized digital therapeutic protocols intended for co-development with pharmaceutical partners as drug-software combinations.

## Achievements

- Peer-reviewed Parkinson’s pilot published in Brain Communications on May 20, 2026.
- Related brain-connectivity research published in npj Parkinson’s Disease in July 2026.
- Announced pharmaceutical collaboration with Merck KGaA in April 2026.
- Reported USD 62 million cumulative funding in August 2026.
- Company lists a startup-of-the-year recognition at Geek Awards Summit 2024.

## Latest updates

- **2026-09** — Appointed Eran Harary, MD, as Chief Medical Officer, announced September 16.
- **2026-08** — Closed USD 36 million Series A; said global Hybridopa Phase III development would commence in Q4 2026.
- **2026-07** — Published further evidence concerning structural and functional connectivity in Parkinson’s disease.
- **2026-05** — Reported Phase IIa results and publication of the Parkinson’s pilot.
- **2026-04** — Announced Merck KGaA collaboration.

## Links

- Website: https://www.remepy.com/
- LinkedIn: https://www.linkedin.com/company/remepy/
- Facebook: https://www.facebook.com/remepyhealth

---

Profile page: https://yespress.io/remepy
Published by YesPress — https://yespress.io
Last updated: 2026-10-03